Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Atossa Genetics Inc

Company price
1.595 USD -0.15 ( 8.86%)
Last update at 2026-11-20T21:00:00Z
VOLUME
48513
Market Cap
23.65M

Momentum Score

…

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.59
Low
1.72
High
52 Week Price Range
1.70
Low
19.35
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.75
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-89.23%
Net Debt
-41.30M
ROCE
-94.38%
Diluted EPS TTM
-4.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -34.77M -25.50M -30.09M -26.96M -20.61M
Net income -34.77M -25.50M -30.09M -26.23M -20.61M
Selling general administrative 15.96M 13.50M 14.04M 12.61M 11.31M
Selling and marketing expenses - - 14.01M - -
Gross profit -0.02M -0.02M -0.02M - -
Reconciled depreciation 0.02M 0.02M 0.01M 0.01M 0.02M
Ebit -37.14M -27.62M -31.38M -27.70M -20.52M
Ebitda -37.12M -27.60M -31.35M -27.69M -20.50M
Depreciation and amortization 0.02M 0.02M 0.02M 0.01M 0.02M
Non operating income net other - - - 0.73M -0.09M
Operating income -37.14M -27.62M -31.38M -27.69M -20.52M
Other operating expenses 37.14M 27.62M 31.38M 27.69M 20.52M
Interest expense - - - -0.01M 0.09M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 2.38M 4.05M 3.78M 0.88M -
Net interest income 2.38M 4.05M 3.78M 0.88M -
Income tax expense - - - -0.73M 0.09M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 37.14M 27.62M 31.38M 27.69M 20.52M
Cost of revenue 0.02M 0.02M 0.02M - -
Total other income expense net 2.37M 2.12M 1.28M 0.73M -0.09M
Net income from continuing ops -34.77M -25.50M -29.83M -26.96M -20.61M
Net income applicable to common shares - - - -26.96M -20.61M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 47.61M 76.44M 96.25M 123.53M 141.26M
Other current assets 4.32M 3.37M 3.65M 2.42M 1.19M
Total liab 8.26M 4.97M 5.24M 5.57M 3.13M
Total stockholder equity 39.35M 71.48M 91.02M 117.96M 138.14M
Other current liab 3.96M 4.29M 4.43M 2.60M 1.41M
Common stock 1.55M 23.49M 22.79M 22.79M 22.79M
Capital stock 1.55M 23.49M - 22.79M 22.79M
Retained earnings -246.56M -211.79M -186.29M -156.19M -129.23M
Other assets - - - 0.64M 0.00M
Cash 41.30M 71.08M 88.57M 110.89M 136.38M
Total current liabilities 8.26M 4.97M 5.24M 5.57M 3.13M
Net debt -41.30M -71.08M -88.57M -110.89M -136.38M
Other stockholder equity 284.37M 259.78M 254.51M 250.78M 244.58M
Property plant equipment - - - - 0.02M
Total current assets 45.62M 74.46M 92.22M 118.20M 141.24M
Long term investments - 0.00M - 4.70M -
Net tangible assets - - - 117.96M 137.55M
Net receivables - - -0.00M 0.74M 1.07M
Inventory - - 1.49M 4.14M 2.60M
Accounts payable 4.29M 0.68M 0.81M 2.96M 1.72M
Accumulated other comprehensive income - - 0.00M - -0.58M
Common stock total equity - - - 22.79M 22.79M
Retained earnings total equity - - - -156.19M -129.23M
Non currrent assets other 1.99M 1.99M 2.32M 0.64M 0.00M
Non current assets total 1.99M 1.99M 4.03M 5.33M 0.02M
Capital lease obligations - - - - 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02M -2.02M -4.73M -0.01M
Change to liabilities - - - 2.44M 0.13M
Total cashflows from investing activities -0.02M -0.02M -0.01M -4.73M -0.01M
Total cash from financing activities 0.00M 3.67M -1.48M 0.00M 113.30M
Change to operating activities - - - -1.85M -1.28M
Net income -34.77M -25.50M -30.09M -26.96M -20.61M
Change in cash -29.79M -17.38M -22.43M -25.49M 96.82M
Begin period cash flow 71.19M 88.57M 111.00M 136.49M 39.66M
End period cash flow 41.41M 71.19M 88.57M 111.00M 136.49M
Total cash from operating activities -29.76M -21.03M -20.94M -20.76M -16.47M
Issuance of capital stock - - - 0.00M 69.67M
Depreciation 0.02M 0.02M 0.02M 0.01M 0.02M
Other cashflows from investing activities - - -0.01M -4.70M -
Change to inventory -0.98M -0.61M 2.54M - -
Change to account receivables - - 0.74M - -
Sale purchase of stock - 0.00M -1.48M - 44.21M
Other cashflows from financing activities - 3.67M -1.47M -4.73M 43.64M
Change to netincome - - - 6.79M 5.27M
Capital expenditures 0.02M 0.02M 0.01M 0.03M 0.01M
Cash flows other operating - - - -3.04M -1.63M
Cash and cash equivalents changes - - - -25.49M 96.82M
Change in working capital 2.35M 0.45M 1.52M -0.60M -1.16M
Stock based compensation 2.65M 2.29M 4.62M 6.79M 5.27M
Other non cash items 2.35M 1.72M 2.99M 0.00M 26.96M
Free cash flow -29.79M -21.05M -20.95M -20.79M -16.48M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ATOS
Atossa Genetics Inc
-0.15
8.86%
1.59 - 7.04 1872.06 0.92 3287.25 2.01
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

448 NW Market Street, Seattle, WA, United States, 98107

206 588 0256

16

Name Title Year Born
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & Pres 1951
Mr. Kyle Guse CPA, Esq., CPA CFO, Gen. Counsel & Sec. 1964
Ms. Heather Rees VP of Fin. & Accounting NA
Ms. Delly Behen P.H.R. VP of Admin. & HR NA
Ms. Janet Rose Rea MSPH, RAC Sr. VP of Regulatory, Quality & Clinical Affairs NA
Dr. Richard Graydon M.D., Ph.D. Interim Chief Medical Officer NA
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, CEO & President 1951
Ms. Heather Rees CPA Senior VP of Finance & Principal Accounting Officer 1973
Ms. Delly Behen P.H.R. Senior Vice President of Administration & HR NA
Mr. Eric Van Zanten Vice President of Investor & Public Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…